|
May 2
|
What Makes Organon (OGN) a New Buy Stock
|
|
May 2
|
Organon Reports Results for the First Quarter Ended March 31, 2024
|
|
Apr 25
|
Earnings Preview: Organon (OGN) Q1 Earnings Expected to Decline
|
|
Apr 8
|
Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024
|
|
Apr 8
|
Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints
|
|
Mar 8
|
On International Women's Day, Organon Canada is encouraging businesses to Invest in HER and help address gender inequities through women's health
|
|
Feb 15
|
Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2023
|
|
Jan 10
|
Organon’s XACIATO™ (clindamycin phosphate) Vaginal Gel 2% Available Nationwide to Treat Bacterial Vaginosis (BV) in Females Aged 12 and Older
|
|
Jan 8
|
Organon affirms 2023 revenue and Adjusted EBITDA guidance and provides 2024 outlook
|
|
Dec 21
|
Organon To Present at the 42nd Annual J.P. Morgan Healthcare Conference
|
|
Dec 18
|
Organon & Lilly Enter Commercialization Agreement in Europe for Two Migraine Medicines
|
|
Apr 27
|
Analysts Estimate Organon (OGN) to Report a Decline in Earnings: What to Look Out for
|